Inventor
WATT ANDREW T
US32 patents
⚠️ This page may combine multiple inventors who share the name “WATT ANDREW T”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ISIS PHARMACEUTICALS INC
25 patentsUS6710174B2Mar 23, 2004
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
ISIS PHARMACEUTICALS INC155 citations99
US6566135B1May 20, 2003
Antisense modulation of caspase 6 expression
ISIS PHARMACEUTICALS INC379 citations99
US6965025B2Nov 15, 2005
Antisense modulation of connective tissue growth factor expression
ISIS PHARMACEUTICALS INC247 citations98
US7709630B2May 4, 2010
Antisense modulation of connective tissue growth factor expression
ISIS PHARMACEUTICALS INC131 citations97
US6656732B1Dec 2, 2003
Antisense inhibition of src-c expression
ISIS PHARMACEUTICALS INC63 citations96
US7846730B2Dec 7, 2010
Antisense modulation of BCL2-associated X protein expression
ISIS PHARMACEUTICALS INC23 citations93
US6734017B2May 11, 2004
Antisense modulation of vascular endothelial growth factor receptor-2 expression
ISIS PHARMACEUTICALS INC27 citations93
US6410324B1Jun 25, 2002
Antisense modulation of tumor necrosis factor receptor 2 expression
ISIS PHARMACEUTICALS INC22 citations93
US6448080B1Sep 10, 2002
Antisense modulation of WRN expression
ISIS PHARMACEUTICALS INC21 citations92
US9650636B2May 16, 2017
Methods for treating hypercholesterolemia
ISIS PHARMACEUTICALS INC5 citations84
US8912160B2Dec 16, 2014
Methods for treating hypercholesterolemia
ISIS PHARMACEUTICALS INC4 citations84
US6468796B1Oct 22, 2002
Antisense modulation of bifunctional apoptosis regulator expression
ISIS PHARMACEUTICALS INC14 citations84
US6867039B2Mar 15, 2005
Antisense modulation of dual specific phosphatase 5 expression
ISIS PHARMACEUTICALS INC6 citations74
US6566132B1May 20, 2003
Antisense modulation of Interferon gamma receptor 1 expression
ISIS PHARMACEUTICALS INC6 citations74
US6870046B2Mar 22, 2005
Antisense modulation of interferon gamma receptor 2 expression
ISIS PHARMACEUTICALS INC4 citations63
US6551826B1Apr 22, 2003
Antisense modulation of raidd expression
ISIS PHARMACEUTICALS INC2 citations63
US6492170B1Dec 10, 2002
Antisense modulation of caspase 9 expression
ISIS PHARMACEUTICALS INC3 citations63
US6410325B1Jun 25, 2002
Antisense modulation of phospholipase A2, group VI (Ca2+-independent) expression
ISIS PHARMACEUTICALS INC5 citations63
US7709453B2May 4, 2010
Modulation of the RNA interference pathway
ISIS PHARMACEUTICALS INC2 citations62
US7427470B2Sep 23, 2008
Antisense modulation of helicase-moi expression
ISIS PHARMACEUTICALS INC2 citations62
US6444466B1Sep 3, 2002
Antisense modulation of helicase-moi expression
ISIS PHARMACEUTICALS INC4 citations62
US6436706B1Aug 20, 2002
Antisense inhibitor of RECQL4 expression
ISIS PHARMACEUTICALS INC2 citations62
US6399378B1Jun 4, 2002
Antisense modulation of RECQL2 expression
ISIS PHARMACEUTICALS INC3 citations62
US6825337B2Nov 30, 2004
Antisense modulation of PLML expression
ISIS PHARMACEUTICALS INC1 citations52
US6468795B1Oct 22, 2002
Antisense modulation of Apaf-1 expression
ISIS PHARMACEUTICALS INC1 citations52
IONIS PHARMACEUTICALS INC
4 patentsUS11530410B2Dec 20, 2022
Methods for treating hypercholesterolemia
IONIS PHARMACEUTICALS INC1 citations73
US10858657B2Dec 8, 2020
Methods for treating hypercholesterolemia
IONIS PHARMACEUTICALS INC2 citations73
US11732265B2Aug 22, 2023
Compositions and methods for modulating complement factor B expression
IONIS PHARMACEUTICALS INC0 citations62
US11926830B2Mar 12, 2024
Modulators of Complement Factor B
IONIS PHARMACEUTICALS INC0 citations61